New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) ...

MiNK Therapeutics (NASDAQ:INKT) stock fell 30% on Monday, paring a massive 730% gain from Friday after William Blair downgraded the shares following the spectacular rally.

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in ...

A research team led by Professor Takuya Yamamoto (Department of Life Science Frontiers) and Professor Yasuhiro Yamada at the University of Tokyo has developed a novel in vivo system that reveals how ...

Cancer does not develop overnight. It can take decades for cancer‐promoting changes in the genome to eventually lead to the ...

MiNK Therapeutics surged on tumor remission data for agenT-797, but financial risks and limited clinical proof remain. Learn ...

MiNK Therapeutics surged 730% on breakthrough testicular cancer data with agenT-797. Click here to read my analysis on INKT ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the ...

MiNK Therapeutics shares soared after the company published a case in a scientific journal of a cancer patient achieving remission after being treated with the company's cell therapy. Shares of the ...

Investing.com -- MiNK Therapeutics, Inc. (NASDAQ: INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with its ...

Shares of MiNK Therapeutics (NASDAQ:INKT) tumbled 30% on Monday, erasing a large portion of the 730% surge seen on Friday after the company’s stock was downgraded by William Blair. The steep rally ...